Biocare Medical (“Biocare”), a leading developer of world class immunohistochemistry (“IHC”) and molecular reagents and instrumentation, is pleased to announce that Luis de Luzuriaga has joined the company as Chief Executive Officer.
Mr. de Luzuriaga has spent his entire career in commercial and executive leadership roles within the life sciences tools and diagnostics sector. Notably, Mr. de Luzuriaga spent six years leading Global Commercial Operations at Leica Biosystems and also served as the Divisional Vice President and General Manager of Abbott Hematology. Most recently, Mr. de Luzuriaga was the CEO of BIT Group (subsidiary of Messer Group), a leading product development and contract manufacturer for high performance clinical, medical and life science devices.
Mr. de Luzuriaga’s proven ability to drive extraordinary growth and industry leadership within the life sciences tools sector aligns well with Biocare’s strong growth trajectory and reputation for quality diagnostic tools focused on the oncology and immunotherapy markets. “Since our first interaction with Luis, it was clear that he had the experience, capabilities and expertise to propel Biocare to the forefront of the industry,” said Ryan Glaws, Partner at Excellere Partners. “His extensive experience and impressive track record at Leica, Abbott and BIT make him the ideal partner to guide Biocare through this exciting and transformational period in the company’s history.”
“I am excited to join Biocare and work with what I know to be both a dynamic and talented team. Having previously competed against Biocare, I know first-hand about the quality of the products and reputation in the marketplace. It is an honor and a privilege to lead this organization, and I am very excited about the future of Biocare,” said Mr. de Luzuriaga.
Biocare is a market leader in IHC and molecular diagnostic reagents and instrumentation, including simultaneous Multiplex IHC solutions that provide increased confidence at critical diagnostic decision points, positively influencing patient therapy while accelerating turnaround time. The company’s customers include clinical and hospital laboratories, pharmaceutical and biotechnology companies, as well as academic, government, and other research institutions. Biocare offers a comprehensive portfolio of integrated reagents and instrumentation to address the rapidly growing diagnostic and research markets for oncology and immunotherapy. The company is headquartered in Pacheco, CA, and serves customers around the globe. Visit www.biocare.net to learn more.
Excellere Partners is a Denver-based private equity firm with $1.36 billion of committed capital across Fund I, Fund II and Fund III, specializing in partnering with entrepreneurs and management teams to build industry leaders. The firm employs a proven research-driven, top down investment strategy, and supports its entrepreneurs and management teams with a proprietary value creation process designed to enhance corporate and operational infrastructure to enable scalability and rapid growth. Excellere’s investments are focused on differentiated and growth-oriented companies positioned to benefit from industry consolidation and favorable macro-economic and demographic trends. The Firm’s targeted industry sectors include healthcare; industrial technology and services; and business services. For more information about Excellere, please visit https://www.excellerepartners.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200311005137/en/
Contacts
Excellere Partners
Tracie Kelly, 303-870-2068
Source: Excellere Partners
View this news release online at:
http://www.businesswire.com/news/home/20200311005137/en
